Given the uncertainty hanging over the economy, it is more important than ever to identify high quality stocks for your portfolio. That means knowing how to find highly profitable companies that are able to fend off competitive threats...
5G3 — TalkMed Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedSmall CapHigh Flyer
- SG$528.04m
- SG$449.67m
- SG$62.14m
- 84
- 34
- 82
- 80
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 2.5% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.23 | ||
| Price to Tang. Book | 6.23 | ||
| Price to Free Cashflow | 24.08 | ||
| Price to Sales | 8.75 | ||
| EV to EBITDA | 15.49 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 29.19% | ||
| Return on Equity | 28.06% | ||
| Operating Margin | 42.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SG$m | 68.91 | 61.36 | 61.28 | 75.92 | 62.14 | 59.9 | 61.6 | -1.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +0.14 | -14.34 | -9.77 | +23.65 | -29.72 | +4.66 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for 5G3
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that these stocks are hard to find - but there are signs that Talkmed SGX:5G3 coul...
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that these stocks are hard to find - but there are signs that Talkmed SGX:5G3 coul...
Profile Summary
TalkMed Group Limited is a Singapore-based investment holding company. The Company’s Oncology services segment is engaged in the provision of oncology services to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., Thu Cuc International General Hospital in Hanoi, Vietnam and Hong Kong Integrated Oncology Centre Holdings Limited. The Company has expanded its oncology services to China. Its Stem cell related products and services segment is engaged in the provision of services related to processing, culturing and storage of stem cells through its subsidiary, Stem Med Pte. Ltd. (Stem Med) to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., StemCord Pte Ltd, the non-controlling shareholder of Stem Med and other individual customers. The Cellular and gene therapy related products and services segment is engaged in the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd.
Directors
- S. Chandra Das NEC (80)
- Peng Tiam Ang CEO (61)
- Boon Yong Lee CFO
- Kei Siong Khoo COO (58)
- Heng Chong Lim SEC
- Anne Low SEC
- Leong Ching Ching NED (52)
- Ching Ching Leong NED (52)
- Jen Howe Lim NED (66)
- Teong Jin Lim NED (64)
- Yock Hian Dan NID (53)
- Yih Pin Sitoh NID (57)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- September 10th, 2013
- Public Since
- January 30th, 2014
- No. of Shareholders
- 958
- No. of Employees
- 53
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Singapore Exchange Securities Trading Ltd
- Shares in Issue
- 1,320,109,347
- Address
- 101 Thomson Road, #09-02 United Square, 307591
- Web
- http://www.talkmed.com.sg/
- Phone
- +65 62586918
- Auditors
- Ernst & Young LLP
Latest News for 5G3
Upcoming Events for 5G3
Talkmed Group Ltd Annual Shareholders Meeting
Similar to 5G3
Alliance Healthcare
Singapore Exchange Securities Trading Ltd
Aoxin Q & M Dental
Singapore Exchange Securities Trading Ltd
AsiaMedic
Singapore Exchange Securities Trading Ltd
Asian Healthcare Specialists
Singapore Exchange Securities Trading Ltd
Asia Vets Holdings
Singapore Exchange Securities Trading Ltd
FAQ
What is the TalkMed share price?
As of Today at 19:11 UTC, shares in TalkMed are trading at SG$0.40. This share price information is delayed by 15 minutes.
How has the TalkMed share price performed this year?
Shares in TalkMed last closed at SG$0.40 and the price had moved by -9.09% over the past 365 days. In terms of relative price strength the TalkMed share price has underperformed the FTSE Developed Asia Pacific Index by -2.21% over the past year.
What are the analyst and broker recommendations for TalkMed?
The overall consensus recommendation for TalkMed is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the TalkMed dividend yield?
The TalkMed dividend yield is 5.13% based on the trailing twelve month period.
Does TalkMed pay a dividend?
Last year, TalkMed paid a total dividend of SG$0.02, and it currently has a trailing dividend yield of 5.13%. We do not have any data on when TalkMed is to next pay dividends.
When does TalkMed next pay dividends?
We do not have data on when TalkMed is to next pay dividends. The historic dividend yield on TalkMed shares is currently 5.13%.
How do I buy TalkMed shares?
To buy shares in TalkMed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TalkMed?
As of the previous close price of SG$0.40, shares in TalkMed had a market capitalisation of SG$528.04m.
Where are TalkMed shares listed?
Here are the trading details for TalkMed:
- Country of listing: Singapore
- Exchange: SES
- Ticker Symbol: 5G3
What kind of share is TalkMed?
Based on an overall assessment of its quality, value and momentum TalkMed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TalkMed share price forecast for 2022?
The analyst consensus target price for shares in TalkMed is SG$0.49. That is 22.5% above the last closing price of SG$0.40.
Analysts covering TalkMed currently have a consensus Earnings Per Share (EPS) forecast of SG$0.02 for the next financial year.
What is the trend in the TalkMed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TalkMed. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +5.82%.
As of the last closing price of SG$0.40, shares in TalkMed were trading -4.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TalkMed PE Ratio?
The TalkMed PE ratio based on its reported earnings over the past 12 months is 20. The shares last closed at SG$0.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TalkMed?
TalkMed's management team is headed by:
- S. Chandra Das - NEC
- Peng Tiam Ang - CEO
- Boon Yong Lee - CFO
- Kei Siong Khoo - COO
- Heng Chong Lim - SEC
- Anne Low - SEC
- Leong Ching Ching - NED
- Ching Ching Leong - NED
- Jen Howe Lim - NED
- Teong Jin Lim - NED
- Yock Hian Dan - NID
- Yih Pin Sitoh - NID